Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans Aug 14, 2017
Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117 Jul 10, 2017
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting Jun 4, 2017
Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting May 8, 2017
Rexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update May 4, 2017
Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update Feb 27, 2017
